Newsroom

DUBLIN--(BUSINESS WIRE)--KBRA releases its 2026 European project finance and infrastructure (PF&I) Sector Outlook, examining themes that will likely take centre stage in 2026 as well as developments and ratings trends from 2025. The European PF&I sector displayed broadly stable credit quality in 2025, and KBRA expects continued stability in 2026. The credit backdrop is supported by modest yet stable economic growth, continued policy support for the renewable/digital transition, a stable...

LOS ANGELES--(BUSINESS WIRE)--Banc of California, Inc. (the “Company”) (NYSE: BANC) today announced it will release financial results for the fourth quarter and fiscal year ended December 31, 2025 after market close on Wednesday, January 21, 2026. The Company will host a conference call to discuss these financial results the following day on Thursday, January 22, 2026, at 10:00 a.m. Pacific Time (PT). Interested parties are welcome to attend the conference call by dialing (888) 317-6003 and ref...

LONDON--(BUSINESS WIRE)--  09-January-2026 Issue: Newday Funding Master Issuer Plc Series 2024-1 Class C RegS XS2768182870 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-December-2025 Date To: 15-January-2026 Record Date: 14-January-2026 Value Date: 15-January-2026 Benchmark Rate: 3.84354% Margin: 2.4% Total Rate: 6.24354% Number of Days: 31 Day Count: Actual / 365L Interest Frequency: Monthly Total...

DUBAI, United Arab Emirates--(BUSINESS WIRE)--Seagate Technology plc (NASDAQ: STX), a global leader in mass‑capacity data storage, is showcasing advanced storage solutions at Intersec 2026 that help power the transformation of AI-driven video analytics into searchable, decision‑ready intelligence. The edge-to-cloud portfolio is designed to help businesses unlock the full value of their data and make smarter, faster decisions. AI applications in video image analytics (VIA) are fueling unpreceden...

WIXOM, Mich.--(BUSINESS WIRE)--Rockwell Medical is a viable alternative supplier in the western U.S., serving customers with a reliable supply chain and high-quality products....

LONDON--(BUSINESS WIRE)--  09-January-2026 Issue: Newday Funding Master Issuer Plc Series 2024-1 Class A Reg S XS2768182284 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-December-2025 Date To: 15-January-2026 Record Date: 14-January-2026 Value Date: 15-January-2026 Benchmark Rate: 3.84354% Margin: 1.18% Total Rate: 5.02354% Number of Days: 31 Day Count: Actual / 365L Interest Frequency: Monthly Tota...

LIÈGE, Belgium & COPENHAGEN, Denmark--(BUSINESS WIRE)--Bio‑Sourcing and Zerion Pharma A/S today announce that their joint project to develop an oral formulation of Trastuzumab, the pioneer monoclonal antibody used to treat breast cancer, has been awarded funding under EUREKA Eurostars. This is Bio‑Sourcing’s second Eurostars success and, together with Zerion’s breakthrough Dispersome® technology, it will support the development of an oral formulation of an anti‑HER2 antibody for the treatment o...

SANTA CLARA, Calif. & TURIN, Italy--(BUSINESS WIRE)--PlusAI, a leader in AI software for autonomous trucks, announced an expansion of its long-standing partnership with IVECO, the commercial vehicle brand of Iveco Group N.V. (EXM: IVG). Together, the companies will launch the first deployment of heavy-duty trucks equipped with Level 4 Autonomous Driving Systems (ADS) in Southern Europe, in collaboration with Spanish logistics operator Sesé and the Government of Aragon. This announcement comes o...

BELLEVUE, Wash.--(BUSINESS WIRE)--Savers Value Village, Inc. (NYSE: SVV), (the “Company”) today announced preliminary net sales for the fourteen weeks ended January 3, 2026 (the "fourth quarter") and the fifty-three weeks ended January 3, 2026 ("fiscal 2025") in conjunction with the Company’s participation in the ICR Conference January 12-14, 2026. The Company’s results for both the fourth quarter and full year ended January 3, 2026 included the benefit of one additional week (the "53rd week")...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for ivonescimab, the novel, first-in-class investigational bispecific antibody, in combination with chemotherapy in second-line or later treatment of patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-squamous non-...